



DIASORIN LAUNCHES THE LIAISON® LEGIONELLA URINARY AG ASSAY IN ALL COUNTRIES ACCEPTING THE CE MARK TO IMPROVE DIAGNOSIS OF LEGIONNAIRES' DISEASE, A SERIOUS TYPE OF PNEUMONIA CAUSED BY LEGIONELLA

THE LIAISON® LEGIONELLA URINARY AG ASSAY:

- IS THE FIRST SOLUTION THAT COMES TO MARKET ALLOWING HIGH-THROUGHPUT QUALITATIVE DETECTION OF *LEGIONELLA PNEUMOPHILA* AND *LEGIONELLA LONGBEACHAE* ANTIGENS;
- DISCRIMINATES LEGIONNAIRES' DISEASE FROM OTHER LUNG INFECTIONS WITH A SIMPLE TEST METHOD;
- IS DEVELOPED TO RUN ON THE LIAISON® CLIA ANALYZERS;
- IS LAUNCHED IN ALL COUNTRIES ACCEPTING THE CE MARK.

Saluggia, July 17, 2023 - DiaSorin (FTSE MIB: DIA) announces the launch of the new LIAISON® Legionella Urinary Antigen Immunodiagnostic Assay in all countries accepting the CE Mark as an aid to the diagnosis of the Legionnaires' Disease (LD), a life-threatening atypical Community Acquired Pneumonia (CAP).

Legionella species are a common cause of CAP in those individuals requiring hospitalization. Misdiagnosed and untreated LD usually worsens rapidly resulting in increased mortality rates. LD death rate may be as high as 40-80% in untreated immuno-suppressed patients and can be reduced to 5-30% through appropriate identification and case management.

The new LIAISON® Legionella Urinary Ag assay improves diagnosis of atypical pneumonia providing a precise identification of the Legionnaires' disease.

The test is performed on the LIAISON® CLIA analyzers and offers a highly automated solution for the microbiology laboratory. With a simple test method, Legionnaires' disease can be identified in only 35 minutes, allowing timely and targeted antimicrobial treatment.

L. pneumophila sg 1 causes from 50 to 80% of Legionnaires' disease cases worldwide. Sg 4 and 6, and the species *L. longbeachae*, *L. micdadei* and *L. bozemanii* are also important in disease, accounting for most of the remaining non-*L. pneumophila* sg 1 cases of LD.

The LIAISON® Legionella Urinary Ag assay with its innovative "dual-antigen" design is able to detect two Legionella's antigens (LPS and PAL) improving sensitivity and specificity. It empowers healthcare professionals to accurately identify *Legionella pneumophila* and *Legionella longbeachae* antigens.

"The launch of this new assay confirms our ability to position DiaSorin as a specialty player, able to provide innovative solutions with a high medical value" commented Chen Even, Chief Commercial Officer of DiaSorin. *"We are confident that our new assay will strongly contribute in discriminating etiological factors in severe atypical pneumonia"*.



The Diagnostic Specialist

PRESS RELEASE



About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 39 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasoringroup.com

For additional information, please contact:

INVESTOR RELATIONS

Riccardo Fava

Corporate VP Communication, ESG & Investor Relations

riccardo.fava@diasorin.it

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst

eugenia.ragazzo@diasorin.it